Hims Stock Dips as New SAFE Drugs Act Targets Compounded Weight-Loss Medications

Hims shares fell after lawmakers proposed the SAFE Drugs Act, a bill that would restrict compounded versions of popular GLP-1 weight-loss drugs. Analysts say the bill could significantly impact Hims’ fastest-growing product category.